Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: Influence on renal function, proteinuria, and morphology

Nephrology Dialysis Transplantation

Volumn 11, Issue 1, 1996, Pages 40-46

  Thaiss, F ^a   Haas, C ^b   Helmchen, U ^a   Wenzel, U ^a   Stahl, R A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Angiotensin converting enzyme; Glomerulonephritis; Proteinuria

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; INULIN; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GLOMERULUS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HISTOLOGY; HYPERTENSION; IMMUNE COMPLEX NEPHRITIS; INULIN CLEARANCE; KIDNEY FUNCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0030031455     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.1.40     Document Type: Article

References (41)

1. Hollenberg NK, Raij I. Angiotensin-converting enzyme inhibition and renal protection. Arch Intern Med 1993; 153: 2426-2435
2. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666
3. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000
4. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46-55
5. Oite T, Batsford SR, Mihatsch MJ, Takamiya H, Vogt A. Quantitative studies of in situ immune complex glomerulonephritis in the rat induced by planted cationized antigen. J Exp Med 1982; 155: 460-474
6. Thaiss F, Mihatsch MJ, Schoeppe W, Stahl RAK. Thromboxane mediates glomerular hemodynamics in a model of chronic glomerular disease. Eur J Clin Invest 1992; 22: 182-189
7. Thaiss F, Schoeppe W, Willaredt-Stoll JG, Batsford S, Mihatsch MJ. Cyclosporin A prevents proteinuria in an active model of membranous nephropathy. Lab Invest 1989; 61: 661-669
8. Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992; 20: 233-241
9. Stahl RAK, Helmchen U, Paravicini M, Ritter LJ, Schollmeyer P. Glomerular prostaglandin formation in two kidney-one-clip hypertensive rats. Am J Physiol 1984; 247: F975-981
10. Führ J, Kaczmarcyzk J, Krüttgen CD. Eine einfache kolorimetrische Methode zur Inulinbestimmung für Nieren-clearanceuntersuchungen bei Stoffwechsel-gesunden und Diabetikern. Klin Wochenschr 1955; 33: 729-730
11. Smith HW, Finkelstein N, Allminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dogs and man. J Clin Invest 1945; 24: 388-404
12. Gröne HJ, Walli A, Gröne E et al. Induction of glomerulosclerosis by dietary lipids. Lab Invest 1989; 60: 433-446
13. Raji L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143
14. Olson JL, Wilson SK, Heptinstall RH. Relation of glomerular injury to preglomerular resistance in experimental hypertension. Kidney Int 1986; 29: 849-857
15. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 1986; 122: 481-487
16. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988; 82: 1757-1768
17. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-596
18. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-1540
19. Wolf G. Vasoactive molecules as regulators of cell growth. Exp Nephrol 1994; 2: 61-62
20. Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics Kidney Int 1984; 25. 857-868
21. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619
22. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensia converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541-549
23. Gohlke P, Lamberty V, Kuwer I et al. Long-term low-dose angiotensin convening enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension 1993; 22: 682-687
24. Bünning P. Kinetic properties of the angiotensin converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1987; 10: S31-S35
25. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989; 35: 654-660
26. Yoshida Y, Fogo A, Shiraga H, Click AD, Ichikawa I. Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney Int 1988; 33: 855-867
27. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36: 626-635
28. Heeg JE, Jong DE, van der Hem GK, de Zeeuw D. Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney Int 1991; 40: 734-741
29. Schmitz PG, O'Donnell MP, Kasiske BL, Katz SA, Keane WF Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Am J Physiol 1992; 263: F496-F502
30. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40: 195-202
31. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31: 752-759
32. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36: 969-977
33. Beukers JB, van der Wal A, Hoedemaeker PJ, Weening JJ. Converting enzyme inhibition and progressive glomerulosclerosis in the rat. Kidney Int 1987; 32: 794-800
34. Beukers JB, Hoedemaeker PJ, Weening JJ. A comparison of the effects of converting-enzyme inhibition and protein restriction in experimental nephrosis. Lab Invest 1988; 59: 631-640
35. Diamond JR. A putative role of hypercholesterolemia in progressive glomerular injury. Annu Rev Med 1992; 43: 83-92
36. Guijarro C, Keane WF Lipid-induced glomerular injury. Nephron 1994; 67: 1-6
37. Pesek-Diamond I, Ding G, Frye J, Diamond JR. Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992; 263: F776-F783
38. Ding G, Pesek-Diamond I, Diamond JR. Cholesterol, macrophases, and gene expression of TGF-ßl and fibronectin during nephrosis. Am J Physiol 1993; 264: F577-F584
39. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 1989; 13: 120-126
40. Rosenberg ME, Hosteller TH. Comparative effects of antihypertensives on proteinuria: angiotensin-converting enzyme inhibitor versus ß1-antagonist. Am J Kidney Dis 1991; 18: 472-482
41. DeJong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? J Am Soc Nephrol 1993; 3: 1333-1341